Search Results 481-490 of 14807 for anti-TNF drugs

  1. Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) - Mayo Clinic

    Treatment with an anti-complement therapy or with Zileuton (Zyflo) within the last three months prior to baseline (Day 1). OCS dose no more than 0.3mg/kg ...

  2. Tetanus Toxoid (Intramuscular Route, Injection Route) Side Effects - Mayo Clinic

    Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

  3. Omeprazole And Sodium Bicarbonate (Oral Route) Before Using - Mayo Clinic

    Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

  4. Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer - Mayo Clinic

    ... anti-tumor necrosis factor [anti-TNF] agents) within 6 weeks prior to cycle 1 day 1: Patients who have received acute, low dose, systemic immunosuppressant ...

  5. Tbo-Filgrastim (Subcutaneous Route) Description and Brand Names - Mayo Clinic

    When certain cancer medicines are used to fight cancer cells, they also affect the white blood cells that fight infections. Tbo-filgrastim is used to ...

  6. Anabolic Steroid (Oral Route, Parenteral Route) Side Effects - Mayo Clinic

    Tumors of the liver, liver cancer, or peliosis hepatis, a form of liver disease, have occurred during long-term, high-dose therapy with anabolic steroids.

  7. Flurbiprofen (Oral Route) Proper Use - Mayo Clinic

    This medicine comes with a Medication Guide. Read and follow the instructions carefully. Ask your doctor if you have any questions. Swallow the tablet whole. Do ...

  8. An Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis - Mayo Clinic

    Treatment with Class Ia or Class III anti-arrhythmic drugs or treatment with two or more agents in combination known to prolong PR interval. Are receiving ...

  9. New treatment option for early type 1 diabetes - Mayo Clinic

    According to findings published in The New England Journal of Medicine in 2023, teplizumab is an anti-CD3 antibody approved for people 8 years and older ...

  10. Torsemide (Oral Route) Before Using - Mayo Clinic

    Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...